reports
- Sean Conroy
SIGA Technologies - Optimizing the TPOXX value proposition
SIGA’s Q124 results were marked by material BARDA and international TPOXX deliveries and highlighted the company’s strategic push towards international expansion, reflected in its revised deal terms with partner Meridian. Robust product revenues of $23.9m (not including $1.6m in R&D income) made up of high margin oral TPOXX deliveries (gross margin upwards of 85%), translated to strong operating profitability of $11.3m compared to an operating loss of $2.1m in Q123. We expect the remaining c $14...
SIGA Reports Financial Results for Three Months Ended March 31, 2024
SIGA Reports Financial Results for Three Months Ended March 31, 2024 Generated Product Sales of $24 Million and Pre-tax Operating Income of $11 MillionCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2024. “SIGA delivered strong results in the first quarter, with product revenues of $24 million and pre-tax operating income of $11 million, both up over the comparable quarter in 2023,”...
SIGA Technologies to Host Business Update Call on May 7 Following Rele...
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at under t...
- Sean Conroy
SIGA Technologies - Positive signals abound
SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth pillar. The amended terms allow the company to actively manage future promotion activities outside the US (effective 1 June 2024). While Meridian will continue to administer existing international contracts, we expect the renegotiated terms to benefit the bottom line in the medium term as SIGA gains...
SIGA Amends International Promotion Agreement with Meridian to Enhance...
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX® NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to mai...
SIGA Names Larry Miller General Counsel
SIGA Names Larry Miller General Counsel NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA’s continued success and growth strategies forward...
- Sean Conroy
SIGA Technologies - Onwards and upwards with strong FY23
SIGA Technologies has delivered its best top-line performance in the last five years, supported by a late surge in TPOXX deliveries across both domestic and international markets. FY23 product revenues grew 50.8% to $130.7m, driven by Q423 BARDA deliveries and international orders, resulting in overall revenues increasing to $139.9m (+26.3% y-o-y). Barring packaging-related bottlenecks, which delayed some deliveries to Q124, there could have been incremental upside to meet our $172.6m revenue es...
SIGA Reports Financial Results for Three and Twelve Months Ended Decem...
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in product reven...
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Declares Special Cash Dividend of $0.60 Per Share Represents a $0.15 Per Share Increase Over 2023 Special Dividend NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023. The dividend is payable on April 11, 2024, to shareholders of record at the close of business on March 26, 2024. ...
SIGA Technologies to Host Business Update Call on March 12th, 2024 Fol...
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024. Participating in the call will be Dr. Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available...
- Sean Conroy
SIGA Technologies - New captain to steer the ship
SIGA Technologies has appointed Dr Diem Nguyen as its new chief executive officer (CEO), effective 27 January 2024. She will be spearheading the company efforts to expand its commercial operations, following the retirement of incumbent CEO, Dr Phil Gomez (who had announced plans to retire in January 2023). Dr Nguyen has over 25 years of experience in the pharmaceutical industry and joins from Xalud Therapeutics, a clinical-stage biotechnology company, where she was the CEO. Prior to Xalud, she s...
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Ex...
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company’s Board of Directors. SIGA’s current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. “The appointment of Diem Nguyen as our new CEO marks a signifi...
- Sean Conroy
SIGA Technologies - International momentum building towards year-end
SIGA recapped several key developments in its Q3 update, signalling strong top-line momentum going into Q423. Most notably, the recent $18m procurement deal with the European Health Emergency Preparedness and Response Authority (HERA) has surprised to the upside, with more value to be unlocked, in our opinion. With upcoming BARDA (oral and IV TPOXX), Department of Defense (DoD) and HERA deliveries, Q423 will likely be a busy quarter for SIGA. We have increased our FY23 product revenue estimates ...
SIGA Reports Financial Results for Three and Nine Months Ended Septemb...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 - In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - In October, Joint Procurement Framework Contract was signed by European Commission with Anticipated Initial Orders by Participating Countries of Approximately $18 Million for Oral TPOXX® (Tecovirimat) - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage ph...
SIGA Technologies to Host Business Update Call on November 7th, 2023 F...
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023. Participating on the call will be Phil Gomez, Chief Executive Officer, Dennis Hruby, Chief Scientific Officer, Dr. Jay Varma, Chief Medical Officer and Daniel Luckshire, Chief Financial...
- Sean Conroy
SIGA Technologies - EU gateway to tap into new international orders
SIGA Technologies has announced the formation by the European Commission of a joint procurement mechanism to source oral TPOXX initially involves 13 countries and is open to all countries in the EU and European Free Trade Association (EFTA). This is in anticipation of an initial $18m order of TPOXX in the next 60 days from EU/EFTA member countries; As such, management expects total (global) orders of $164m in FY23. This development allows participating EU/EFTA member countries to acquire courses...
SIGA Announces Creation of Joint Procurement Mechanism by European Com...
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation by the European Commission’s DG (Health Emergency Preparedness and Response Authority) of a joint procurement mechanism under which 13 participating countries from the European Union (EU) and the E...
- Sean Conroy
SIGA Technologies - Notable CMO appointment to position for growth
SIGA Technologies has announced the appointment of Dr Jay K Varma as executive vice president and chief medical officer, while he remains a director on the board. Leveraging his prior leadership roles managing COVID-19 and other infectious diseases, Dr Varma will have practical insights that could aid SIGA’s efforts in raising awareness of infectious diseases and could enhance the company’s global procurement and treatment strategies. We believe Dr Varma’s appointment could support efforts for g...
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Offi...
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO). He will also continue to serve as a director of the SIGA Board of Directors. “As SIGA has worked to support the global response to the MPOX outbreak and as we continue to expand our role in planning for the prevention and treatmen...
- Sean Conroy
SIGA Technologies - Second quarter as expected, onward to H223
SIGA has reported Q223 results, which came in largely as expected, and management has provided key operational highlights. Activity in the second half of the year has started to firm up with upcoming TPOXX deliveries (for H223) and better-than-expected international orders (offsetting IV orders that will likely be received in FY24). We maintain our FY23 product revenue estimate of $155m and note H223 management sales guidance of $143–158m. We await further clarity on PEP immunogenicity trials, w...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.